SMILE body project: protocol for a randomized controlled trial of an online eating disorder prevention program in young women with psychiatric disorders
Abstract
Aim: Young women with psychiatric illness have an increased susceptibility for eating disorders (ED); however, no prevention initiatives have been tested for this group. The Body Project ED prevention program has produced promising effect on ED symptoms, body satisfaction, and future ED onset; however, no studies have investigated this specific vulnerable group. In SMILE Body Project, we adapted the Body Project manual to a psychiatric population. In this protocol paper, we describe the randomized controlled trial (RCT) to evaluate the efficacy of the SMILE Body Project.
Methods: This is an ongoing RCT including 300 young women between 15 and 30 years with a psychiatric illness and subjective body dissatisfaction, starting May 2025. Participants are randomized to either online Body Project groups or an active control arm based on expressive writing exercises. The primary aim is to test if SMILE Body Project significantly reduces the incidence of ED in women with psychiatric illness after 2 years compared to controls. The secondary aim is to explore changes in ED symptoms, psychiatric symptoms, QoL, and predictors such as psychiatric symptoms and time spent on social media.
Results: We expect that SMILE Body Project will effectively reduce the incidence of ED diagnosis compared to controls. In addition, we anticipate new knowledge on how time spent on social media affects body image in women with psychiatric illness.
Conclusions: If SMILE Body Project proves efficacious, it…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 300 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.